Clinical Trial Diversity and Inclusion Plan Designer for FDA Draft Guidance Compliance for Audit Readiness Internal Audit Week for Compliance Review Change Review Cycle for Service Reliability Review Scenario 0135
Designs a comprehensive Diversity and Inclusion Plan for a Phase III clinical trial aligned to FDA's 2022 Draft Guidance on Diversity Action Plans, specifying enrollment targets, site selection criteria, and retention strategies by demographic group.